Publications by authors named "Anne Floquet"

Claim this Profile
A
Author Correction: Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques

Nat Commun· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Gilles Freyer, Anne Floquet, Olivier Tredan, Aurore Carrot, Carole Langlois-Jacques

Nat Commun· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic profile analysis of leiomyomas with bizarre nuclei and fumarate hydratase deficient leiomyomas: Strengths, weaknesses, and limitations of array-CGH interpretation.
Quitterie Fontanges, Paul Dubos, Tom Lesluyes, Yec'han Laizet, Valérie Velasco, Anne Floquet

Genes Chromosomes Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial.
Michel Fabbro, Pierre-Jean Lamy, Célia Touraine, Anne Floquet, Isabelle Ray-Coquard

Front Oncol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Market opportunities seizing capability and fish farming firm performance: A dynamic managerial capability perspective.
Albertine M Houessou, Augustin K N Aoudji, Gauthier Biaou, Anne Floquet

Heliyon· August 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients. A TMRG and GINECO group study.
Brunhilde Hanvic, Fabrice Lecuru, Hélène Vanacker, Patricia Pautier, Fabrice Narducci, Anne Floquet

Gynecol Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Olaparib First-Line Maintenance Monotherapy in BRCA-Mutated Epithelial Ovarian Cancer: Descriptive Analysis of the First French Real-World Data Study.
Charlotte Bellier, Laurence Gladieff, Fanny Le Du, Dominique Berton, Charlotte Bonnard, Anne Floquet

Drugs Real World Outcomes· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibitors (PARPi) prolongation after local therapy for oligo-metastatic progression in relapsed ovarian cancer patients.
Thibault Gauduchon, Maria Kfoury, Domenica Lorusso, Anne Floquet, Jole Ventriglia

Gynecol Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
One-Year Follow-Up of Seroprevalence of SARS-CoV-2 Infection and Anxiety among Health Workers of a French Cancer Center: The PRO-SERO-COV Study.
Brice Richez, Coralie Cantarel, Françoise Durrieu, Isabelle Soubeyran, Julie Blanchi, Anne Floquet

Int J Environ Res Public Health· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dissecting the Origin of Heterogeneity in Uterine and Ovarian Carcinosarcomas.
Anne-Sophie Sertier, Anthony Ferrari, Roxane M Pommier, Isabelle Treilleux, Sandrine Boyault, Anne Floquet

Cancer Res Commun· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of chemotherapy according to status in patients with high-grade serous ovarian carcinoma at first platinum-sensitive relapse.
Flora Brouillard-Saby, Caroline Saint-Martin, Isabelle Ray-Coquard, Laurence Gladieff, Christophe Pomel, Anne Floquet

Int J Gynecol Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Uterine leiomyosarcoma - French guidelines from the GSF/NETSARC and TMRG groups].
Bérénice Collineau, Catherine Genestie, Sabrina Croce, Pierre Meeus, Anne Floquet

Bull Cancer· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial.
Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Becourt, Nicolas Delanoy, Florence Joly, Anne Floquet

Gynecol Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical restaging of patients with early‑stage endometrial cancer with lymphovascular invasion does not significantly impact their survival outcomes.
Beatriz Navarro, Chrysoula Margioula-Siarkou, Stamatios Petousis, Anne Floquet, Guillame Babin

Oncol Lett· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial.
Paul DiSilvestro, Susana Banerjee, Nicoletta Colombo, Giovanni Scambia, Byoung-Gie Kim, Anne Floquet

J Clin Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Avelumab in patients with gestational trophoblastic tumors with resistance to polychemotherapy: Cohort B of the TROPHIMMUN phase 2 trial.
Benoit You, Pierre-Adrien Bolze, Jean-Pierre Lotz, Jérome Massardier, Laurence Gladieff, Anne Floquet

Gynecol Oncol· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Practical management of PARP inhibitors: A French DELPHI consensus].
Frédéric Selle, Jean-Jacques Boffa, Gabriel Etienne, Antoine Angelergues, Paule Augereau, Anne Floquet

Bull Cancer· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimal timing of interval debulking surgery for advanced epithelial ovarian cancer: A retrospective study from the ESME national cohort.
Quentin Dominique Thomas, Amal Boussere, Jean-Marc Classe, Christophe Pomel, Hélène Costaz, Anne Floquet

Gynecol Oncol· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ study.
Florence Joly, Michel Fabbro, Dominique Berton, Justine Lequesne, Amélie Anota, Anne Floquet

Gynecol Oncol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival impact of histological response to neoadjuvant chemotherapy according to number of cycles in patients with advanced ovarian cancer.
Sarah Betrian, Martina Aida Angeles, Antonio Gil Moreno, Bastien Cabarrou, Marion Deslandres, Anne Floquet

Int J Gynecol Cancer· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Data on Newly Diagnosed -Mutated High-Grade Epithelial Ovarian Cancers: The French National Multicenter ESME Database.
Marta Bini, Stanislas Quesada, Pierre Meeus, Manuel Rodrigues, Eric Leblanc, Anne Floquet

Cancers (Basel)· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Surgical Implications of Advanced Low-Grade Serous Ovarian Cancer: Analysis of the Database of the Tumeurs Malignes Rares Gynécologiques Network.
Hélène Bonsang-Kitzis, Nabilah Panchbhaya, Anne-Sophie Bats, Eric Pujade-Lauraine, Patricia Pautier, Anne Floquet

Cancers (Basel)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of Navitoclax (ABT-263) as single agent in women heavily pretreated for recurrent epithelial ovarian cancer: The MONAVI - GINECO study.
Florence Joly, Michel Fabbro, Philippe Follana, Justine Lequesne, Jacques Medioni, Anne Floquet

Gynecol Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers Associated with Lymph Nodal Metastasis in Endometrioid Endometrial Carcinoma.
Mathilde Mairé, Aurélien Bourdon, Isabelle Soubeyran, Carlo Lucchesi, Frédéric Guyon, Anne Floquet

Cancers (Basel)· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the geriatric vulnerability score in older patients with ovarian cancer: an analysis from the GCIG-ENGOT-GINECO EWOC-1 study.
Claire Falandry, Fanny Pommeret, Laurence Gladieff, Fabien Tinquaut, Domenica Lorusso, Anne Floquet

Lancet Healthy Longev· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis